Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.

The federal 340B Drug Pricing Program — a noble idea first enacted in 1992 — needs to be brought back into the shop for ...

Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals ...

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

The 340B program's “covered entities” serve low-income, poorer populations that tend to be un- or underinsured. Many, if not ...

Discover how the 340B drug pricing program, intended to help low-income patients, has become a system of abuse and misuse ...

Learn about the legal battle between Bristol Myers Squibb and the HHS over the 340B drug pricing program, as other drugmakers join in with rebate plans.

Minnesota releases a report on the 340B Drug Pricing Program, highlighting the need for transparency in healthcare economics.

The drugmaker looks to rein in how it gives discounts in a federal program designed to help hospitals that serve low-income ...

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...